PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Tao Feng

Jiaxing University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · JOURNAL ARTICLE

Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with iruplinalkib resistance

Frontiers in Pharmacology

Single-case report of a treatment strategy in a rare ALK variant; describes clinical response but lacks control group, quantified endpoints, or generalizable evidence.

PreliminaryLung Cancer Research Studies Linfeng Cao Tao Feng

Reported

Time to progression on iruplinalk…6.3 months

Iruplinalkib dose180 mg once daily

Lorlatinib dose100 mg once daily

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support